AbbVie stock price: ABBV ends higher into weekend, with India patent setback and Feb. 4 earnings in focus

24 January 2026

New York, Jan 24, 2026, 10:54 EST — Market closed.

AbbVie shares climbed 0.5% Friday, finishing at $219.26.
The drugmaker will release its full-year and fourth-quarter results on Feb. 4.
Indian media reported that a patent office has rejected an application connected to AbbVie’s cancer drug venetoclax.

AbbVie shares closed Friday 0.53% higher at $219.26, securing a slightly stronger position ahead of the weekend shutdown of U.S. markets.

That modest shift carries weight as the stock approaches the final stretch before AbbVie’s upcoming earnings report, where guidance and pipeline news often set the tone for what comes next. With the next U.S. session on Monday, traders will be watching closely to see if new developments overseas shake market sentiment.

AbbVie is also caught in a market that’s grown wary again, driving some investors to favor large, dividend-heavy healthcare stocks when they shy away from risk. But that defensive demand can evaporate fast if the company’s guidance falls short.

AbbVie’s shares fluctuated between $215.88 and $219.82 on Friday, with roughly 5.8 million shares exchanging hands, per Yahoo Finance.

The stock outpaced some big pharma rivals during the session. Johnson & Johnson gained 0.76%, while Pfizer dipped 0.08%, according to MarketWatch data.

U.S. stocks ended a volatile week on a muted note. The S&P 500 eked out a 0.1% gain Friday, while the Dow slipped 0.6%, and the Nasdaq climbed 0.3%, according to an Associated Press market recap.

AbbVie’s next major event is its earnings release. The company plans to report full-year and Q4 2025 results on Wednesday, Feb. 4, before markets open. A conference call will follow at 8 a.m. Central time.

Investors will focus on updates about how the company plans to counteract declines in older products with new therapies and deals, plus any shifts in 2026 forecasts. Pricing, rebates, and competition usually carry as much weight as the financials themselves.

There’s a new setback overseas. On Friday, The Times of India reported that India’s patent office denied AbbVie’s application for venetoclax, known as Venclexta. This move might open the door for generic versions. The office ruled the application lacked an “inventive step,” a key patent law requirement. https://timesofindia.indiatimes.com/india/patent-rejected-for-mncs-cancer-drug-generics-to-follow/articleshow/127206094.cms

The immediate test for the stock arrives when trading picks up again Monday. But the more significant moment is Feb. 4, when AbbVie reports its results and outlook, setting a fresh benchmark for ABBV’s price.

Khadija Saeed Latest posts

Khadija Saeed is a financial markets reporter at TS2.tech. Her coverage ranges from stocks and technology to emerging industries and developments across global markets. She studied economics and finance at the London School of Economics and worked in market research before becoming a financial journalist. Follow Khadija Saeed on Google News.

View all